Who is eligible for clinical trial NCT05719714?

Participants must meet the protocol's inclusion criteria for Chronic Kidney Diseases. The stated age range is 18 Years to 85 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT05719714 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-28

Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease (NCT05719714)

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Northwestern University

🩺 Plain-English Summary (8th-Grade Level)

The goal of this study is to better understand the effects of a sodium-glucose transport protein 2 inhibitor, dapagliflozin, added on to standard of care on heart and lung function and circulating metabolites (substances created when our bodies break down food, drugs, or its own tissues) in patients with chronic kidney disease.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (4 items) and avoid the listed exclusions (20 items).

Location: Northwestern University — Chicago, Illinois

Age range: 18 Years to 85 Years

🧪 Interventions in This Study

Dapagliflozin 10 MG [Farxiga] (DRUG)

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

\>18 years of age
eGFR 25-60 ml/min/1,73m2 (eGFR = estimated glomerular filtration rate)
On stable doses of diuretics and/or angiotensin converting enzyme inhibitor or angiotensin receptor blocker
Evidence of subclinical heart failure with preserved ejection fraction at their pre-exercise echocardiogram (defined as meeting 3/5 of the American Society of Echocardiography (ASE) criteria for diastolic dysfunction \[septal e'\<7 cm/wc, average E/e' ratio\>14, left atrial volume index \>34 mL/m2, and peak TR velocity \>2.8 m/sec\] or absolute left ventricular longitudinal strain \< 18%, left atrial reservoir strain (LARS) \< 25% on 2d speckle tracking echocardiography), lack of augmentation of LVLS or LARS during exercise, or peak VO2 Females: ≤ 18 mL/kg/min, peak VO2 Males: ≤ 20 mL/kg/min on cardiopulmonary exercise testing.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
presence or history of diabetes
coronary revascularization within the last 6 months
hemodynamically significant valvular disease
significant lung disease requiring home oxygen
angina (chest pain)
non-revascularized myocardial ischemia
systolic BP \<100 or \>180 mmHg
pregnancy
clinical heart failure symptoms
history of systemic disease processes that can cause HFpEF such as amyloidosis or sarcoidosis
any musculoskeletal or chronic condition that will interfere with completion of cardiac testing

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

Northwestern University — Chicago, Illinois

📞 Contact the Study Coordinator

Phone: (855) 692-6482

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Chronic Kidney Diseases

Evaluation of Increased Fruits and Vegetables Consumption in Chronic Kidney Disease — Port Jefferson Station, New York
Transitioning to Home or In-center Dialysis — Montreal, Quebec
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for CKD — St John's,
Chronic Kidney Disease-Education (CKD-EDU) — Brockport, New York
Quality of Life in Patients Transitioning to Home or In-Center Dialysis (QUALIFY CKD-to-HOME) — Montreal, Quebec
Interactive Computer-adaptive Chronic Kidney Disease Education Program — Chicago, Illinois

Explore by condition: All Chronic Kidney Diseases clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗